Thus, PARP1 inhibitors should be reserved for clinical use when BRCA2 LOH can be verified in the tumour, assessment of which emerges as a critical requirement in the design of human clinical trials for the treatment of BRCA2‐deficient cancers. This evidence concerns the gene BRCA2 and neoplasm.